Biglycan reduces body weight by regulating food intake in mice and improves glucose metabolism through AMPK/AKT dual pathways in skeletal muscle. Issue 8 (27th July 2021)

• Record Type: Journal Article
• Authors: Chung, InHyeok; Kim, Shin Ae; Kim, Seolsong; Lee, Jung Ok; Park, Clara Yongjoo; Lee, Juhee; Kang, Jun; Lee, Jin Young; Seo, Ilhyeok; Lee, Hye Jeong; Han, Jeong Ah; Kang, Min Ju; Lim, Eunice; Kim, Su Jin; Wu, Sang Woo; Oh, Joo Yeon; Chung, Ji Hyung; Kim, Eun‐Kyoung; Kim, Hyeon Soo; Shin, Min‐Jeong
• Is Part Of: FASEB journal. Volume 35:Issue 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-07-27
• Subjects: AKT -- AMPK -- biglycan -- food intake -- glucose uptake -- obesity; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202002039RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: While biglycan (BGN) is suggested to direct diverse signaling cascades, the effects of soluble BGN as a ligand on metabolic traits have not been studied. Herein, we tested the effects of BGN on obesity in high‐fat diet (HFD)‐induced obese animals and glucose metabolism, with the underlying mechanism responsible for observed effects in vitro. Our results showed that BGN administration (1 mg/kg body weight, intraperitoneally) significantly prevented HFD‐induced obesity, and this was mainly attributed to reduced food intake. Also, intracerebroventricular injection of BGN reduced food intake and body weight. The underlying mechanism includes modulation of neuropeptides gene expression involved in appetite in the hypothalamus in vitro and in vivo. In addition, BGN regulates glucose metabolism as shown by improved glucose tolerance in mice as well as AMPK/AKT dual pathway‐driven enhanced glucose uptake and GLUT4 translocation in L6 myoblast cells. In conclusion, our results suggest BGN as a potential therapeutic target to treat risk factors for metabolic diseases.